Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Daniel Tylawsky"'
Publikováno v:
Cancer Research. 83:1992-1992
Medulloblastoma (MB) is the most common malignant pediatric brain tumor with ~30% mediated by Sonic hedgehog (SHH) signaling. While SHH effector Smoothened inhibition is promising, therapeutic index is reduced by high systemic doses required for suff
Publikováno v:
The Journal of the Acoustical Society of America. 153:A32-A32
P-selectin is a nanotherapeutic target for enhanced passage of nanoscale drug delivery systems across the vascular barrier and into tumors via transcytosis. While many tumors express P-selection, radiation can be used to induce expression in tumors d
Autor:
Yosi Shamay, Matthew B. Greenblatt, Praveen Raju, Taseen Islam, Jeffrey Gerwin, Jake Vaynshteyn, Hiro Kiguchi, Daniel Tylawsky, Daniel R. Boue, Janki Shah, Matija Snuderl, Daniel A. Heller
Medulloblastoma (MB) is the most common malignant pediatric brain tumor with ~30% mediated by Sonic hedgehog (SHH) signaling. While SHH effector Smoothened inhibition is promising, therapeutic index is reduced by high systemic doses required for suff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcb603f620ffe31aff75535bddfa1335
https://doi.org/10.21203/rs.3.rs-658944/v1
https://doi.org/10.21203/rs.3.rs-658944/v1
Autor:
Praveen Raju, Daniel Tylawsky, Jake Vaynshteyn, Jeffrey Gerwin, Daniel Heller, Matija Snuderl
Publikováno v:
Neuro-Oncology. 24:i126-i126
The histone-lysine N-methyltransferase EZH2 is the catalytic component of the PRC2 complex and is overexpressed in several medulloblastoma subtypes. However, its role in medulloblastoma tumorigenesis has been shown to be context-dependent using genet
Autor:
Hiroto Kiguchi, Mandana Manzari, Jake Vaynshteyn, Jeffrey Gerwin, Daniel Tylawsky, Na Li, Janki Shah, Yosi Shamay, Matthew Greenblatt, Daniel Heller, G Praveen Raju
Publikováno v:
Neuro Oncol
OBJECTIVE The Sonic Hedgehog (SHH) medulloblastoma subgroup accounts for ~25% of all cases and has an intermediate prognosis. Current conventional therapies result in devastating morbidities including intellectual disability and secondary malignancie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c875c5984b4aa4bca157751c857ed738
https://europepmc.org/articles/PMC6846632/
https://europepmc.org/articles/PMC6846632/
Autor:
Daniel A. Heller, Matthew B. Greenblatt, Daniel Tylawsky, Jeffrey Gerwin, Na Li, Praveen Raju, Janki Shah, Hiro Kiguchi, Jake Vaynshteyn, Mandana T. Manzari, Yosi Shamay
Publikováno v:
Neuro-Oncology
OBJECTIVE The Sonic Hedgehog (SHH) medulloblastoma subgroup accounts for ~25% of all cases and has an intermediate prognosis. Current therapies result in devastating morbidities including intellectual disability and secondary malignancies. Although m